Evidence map›Paper›PMID 34931119›Full record

ArticleInternational journal of peptide research and therapeutics2022

Pierce into Structural Changes of Interactions Between Mutated Spike Glycoproteins and ACE2 to Evaluate Its Potential Biological and Therapeutic Consequences.

Zahra Sadat Hashemi, Mahboubeh Zarei, Shaden M H Mubarak, Anahita Hessami, Maysam Mard-Soltani, Bahman Khalesi, Alireza Zakeri, Mohammad Reza Rahbar, Abolfazl Jahangiri, Navid Pourzardosht and 1 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of peptide research and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Zahra Sadat HashemiATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Mahboubeh ZareiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Shaden M H MubarakDepartment of Clinical Laboratory Science, Faculty of Pharmacy, University of Kufa, Najaf, Iraq.
Anahita HessamiSchool of Pharmacy, Shiraz University of medical sciences, Shiraz, Iran.
Maysam Mard-SoltaniDepartment of Clinical Biochemistry, Faculty of Medical Sciences, Dezful University of Medical Sciences, Dezful, Iran.
Bahman KhalesiDepartment of Research and Production of Poultry Viral Vaccine, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Alireza ZakeriDepartment of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran.
Mohammad Reza RahbarPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abolfazl JahangiriApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Navid PourzardoshtBiochemistry Department, Guilan University of Medical Sciences, Rasht, Iran.
Saeed KhaliliDepartment of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran.ORCID 0000-0003-0493-9595
Shiraz University of Medical Sciences · IRShahid Rajaee Teacher Training University · IRAcademic Center for Education, Culture and Research · IRBaqiyatallah University of Medical Sciences · IRDezful University of Medical Sciences · IRGuilan University of Medical Sciences · IRRazi Vaccine and Serum Research Institute · IRUniversity of Kufa · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The structural consequences of ongoing mutations on the SARS-CoV-2 spike-protein remains to be fully elucidated. These mutations could change the binding affinity between the virus and its target cell. Moreover, obtaining new mutations would also change the therapeutic efficacy of the designed drug candidates. To evaluate these consequences, 3D structure of a mutant spike protein was predicted and checked for stability, cavity sites, and residue depth. The docking analyses were performed between the 3D model of the mutated spike protein and the ACE2 protein and an engineered therapeutic ACE2 against COVID-19. The obtained results revealed that the N501Y substitution has altered the interaction orientation, augmented the number of interface bonds, and increased the affinity against the ACE2. On the other hand, the P681H mutation contributed to the increased cavity size and relatively higher residue depth. The binding affinity between the engineered therapeutic ACE2 and the mutant spike was significantly higher with a distinguished binding orientation. It could be concluded that the mutant spike protein increased the affinity, preserved the location, changed the orientation, and altered the interface amino acids of its interaction with both the ACE2 and its therapeutic engineered version. The obtained results corroborate the more aggressive nature of mutated SARS-CoV-2 due to their higher binding affinity. Moreover, designed ACe2-baased therapeutics would be still highly effective against covid-19, which could be the result of conserved nature of cellular ACE2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10346-1.

Indexed as

Lineage B.1.1.7.MutationSARS-CoV-2Spike proteinStructural analyses

Identifiers

PMID34931119
PMCPMC8674523
OpenAlexW4200429184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.